Gantt Chart for Medical Device Launch

Medical device commercialization is one of the most regulated and schedule-sensitive processes in any industry. FDA review clocks run independently of your internal planning. Manufacturing validation has mandatory documentation stages. And clinical data requirements can change if FDA issues an additional information request mid-review. Without a Gantt chart that shows every dependency, teams consistently underestimate the time from final design to first commercial shipment — and underestimating that timeline in a VC-backed medical device company is an existential risk.

A Gantt chart for medical device launch maps the full pre-commercial journey: regulatory strategy, quality system establishment, design verification and validation, manufacturing process validation, FDA submission, post-clearance scale-up, and commercial launch activities. Every phase has external dependencies — FDA review clock, notified body schedules for CE marking, GPO contracting cycles — that must appear on the timeline as fixed points the internal schedule bends around.

FDA Regulatory Pathway as the Critical Path Anchor

The first planning decision is regulatory pathway, because it determines the timeline by 12–18 months.

510(k) clearance applies to Class II devices substantially equivalent to a legally marketed predicate. FDA's target review time for a standard 510(k) is 90 days from acceptance. Acceptance review itself takes 15 days. If FDA sends an Additional Information (AI) request, the clock stops until the sponsor responds — a common 30–60 day delay. Total 510(k) timeline from submission to clearance: typically 4–9 months in practice, depending on complexity and AI requests.

De Novo classification applies to novel low-to-moderate risk devices without a predicate. FDA targets 150 days for De Novo review, but actual times frequently exceed this.

Premarket Approval (PMA) applies to Class III high-risk devices. The standard PMA review period is 180 days, but PMA applications require clinical data from controlled trials, which adds 2–5 years upstream before submission. PMA supplements for manufacturing changes or labeling updates have their own review timelines.

CE marking under MDR 2017/745 (for EU market access) involves a notified body audit of the technical file and QMS. Notified body capacity constraints have extended CE marking timelines to 12–24+ months in recent years. Plan EU regulatory in parallel with FDA, not sequentially.

Plot the FDA submission date as a fixed gate on the Gantt. Work backward from target clearance to set the submission date, then work backward from the submission date to set design verification/validation completion, manufacturing validation completion, and QMS certification.

Phase 1: Regulatory Strategy and QMS Establishment (Months 1–4)

Regulatory strategy finalizes pathway selection, predicate identification (for 510(k)), and submission type. Engage a regulatory affairs specialist or consultant early. If substantial equivalence is unclear, request a Pre-Sub meeting with FDA (formerly known as Q-Sub). Pre-Sub meetings add 60–90 days but can prevent a Not Substantially Equivalent (NSE) determination that restarts the clock.

ISO 13485 Quality Management System establishment is not optional for FDA registration and is required for CE marking. ISO 13485 is the medical device-specific QMS standard covering design controls, risk management (ISO 14971), supplier controls, document control, CAPA, complaint handling, and post-market surveillance. For a startup, building from scratch takes 6–12 months. Using a contract manufacturing organization (CMO) with existing ISO 13485 certification shortens this, but the device company still needs its own QMS for design controls.

Design controls under 21 CFR Part 820 (and the new QMSR aligning to ISO 13485) require documented design input, design output, design review, design verification, design validation, and design transfer. These are not paperwork exercises — they are the traceability chain from user needs to finished device that FDA reviewers audit.

Key milestone: ISO 13485 certification achieved; design controls documentation initiated.

Phase 2: Clinical Evaluation and Testing (Months 3–8)

Clinical evaluation plan (CEP) defines the clinical data strategy. For a 510(k), this often involves a literature review of the predicate and clinical comparators plus bench testing, without a clinical trial. For De Novo or PMA, clinical data from a controlled study may be required.

Bench testing covers performance testing against predicate or intended use specifications, electrical safety (IEC 60601 series for electrical medical devices), biocompatibility per ISO 10993, and sterilization validation if the device is sterile.

Usability testing under IEC 62366-1 evaluates whether users can operate the device safely and effectively. Formative studies inform design; summative testing with representative users generates the data included in the regulatory submission.

Software verification and validation under IEC 62304 applies if the device contains software. Software of unknown provenance (SOUP) documentation and cybersecurity risk analysis (per FDA's 2023 cybersecurity guidance) are required for connected devices.

Key milestone: Design Freeze (no further design changes without formal change control); V&V testing complete.

Phase 3: Manufacturing Process Validation (Months 6–10)

Manufacturing process validation — Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) — is required before the manufactured device can be used in clinical studies or included in a PMA submission, and before commercial manufacturing begins.

IQ verifies that equipment is installed correctly and operates within specified tolerances.

OQ tests that the process produces acceptable output across the anticipated operating range.

PQ demonstrates process consistency across multiple production runs under actual production conditions.

Process validation takes 3–6 months depending on complexity. It cannot start until manufacturing equipment is installed and calibrated. If the device is manufactured by a CMO, the sponsor must audit the CMO's processes and ensure their validation protocols meet FDA requirements.

Shelf-life and accelerated aging studies for devices with sterile barrier systems or time-sensitive components must run in parallel. Real-time aging takes as long as the claimed shelf life; accelerated aging per ASTM F1980 compresses this but both are typically required.

Key milestone: IQ/OQ/PQ complete; process validation report approved; manufacturing ready for commercial production.

Phase 4: Labeling Compliance and Regulatory Submission (Months 8–12)

Labeling compliance under 21 CFR Part 801 governs device labels, package inserts, and Instructions for Use (IFU). Required elements include device name, manufacturer name and address, lot/serial number, expiration date, directions for use, and contraindications. For in vitro diagnostic devices, 21 CFR Part 809 applies. UDI (Unique Device Identification) labeling under 21 CFR Part 830 requires registration in FDA's GUDID database.

510(k) submission assembly compiles the substantial equivalence argument, predicate comparison table, performance testing data, biocompatibility data, software documentation (if applicable), and labeling. The eCopy must meet FDA formatting requirements; deficiencies in format cause acceptance failures that reset the timeline.

FDA submission → acceptance review (Day 1–15) → substantive review (Days 16–90) is the standard 510(k) clock. AI requests pause the clock. Track the AI response deadline as a hard milestone on the Gantt — FDA closes files that go unanswered.

Key milestone: 510(k) Accepted (Day 1 of review clock); Clearance Received.

Phase 5: Post-Clearance Commercial Launch (Months 12–18)

FDA establishment registration and device listing must be completed before commercial distribution. Registration is annual; the registration window opens October 1.

Manufacturing scale-up begins after clearance. Pre-clearance manufacturing is limited (clinical samples, test batches). Post-clearance, production volumes ramp to meet commercial demand projections.

Distribution network setup involves contracting with stocking distributors, negotiating GPO (Group Purchasing Organization) contracts, and credentialing with hospital supply chain departments. GPO contract cycles often have specific bid windows — missing a cycle delays hospital system access by 12 months.

Field service engineer (FSE) training is required before any customer-facing service or installation work begins. FSEs need device operation training, troubleshooting protocols, and documentation practices for service records.

Commercial launch triggers post-market surveillance plan activation. MDR (Medical Device Reporting) obligations require manufacturers to report device malfunctions, serious injuries, and deaths within defined timeframes (30 days for most reportable events, 5 days for events requiring immediate remediation).

Key milestones: Establishment registration complete; first stocking distributor contracted; commercial launch date; first MDR submission training complete.

Structuring the Medical Device Launch Gantt

Build the Gantt with these primary workstreams as swim lanes:

1. Regulatory Affairs (pathway strategy, Pre-Sub, submission, clearance)
2. Quality System (ISO 13485, design controls, CAPA)
3. Engineering / V&V (design verification, validation testing, design freeze)
4. Manufacturing (equipment procurement, process validation, scale-up)
5. Regulatory Compliance (labeling, UDI, establishment registration)
6. Commercial (distribution contracting, GPO, FSE training, launch)

The critical path typically runs: Design Freeze → V&V complete → Manufacturing validation complete → FDA submission → Clearance → Commercial launch. Every other workstream must complete before its corresponding gate on this critical path.

Use red milestones for externally fixed dates: FDA review clock start, AI request response deadline, GPO bid window close. These cannot move; the internal schedule adjusts around them.

Common Timeline Failures

Underestimating process validation duration. Validation protocols take weeks to write, equipment must be procured and installed before IQ begins, and PQ failures require investigation and re-run. Add 30% buffer to process validation estimates.

Starting ISO 13485 too late. Certification requires a third-party audit after the QMS is implemented and has generated records. Audits are scheduled months in advance. Starting QMS work after design freeze means certification will delay submission.

Not accounting for AI request response time. An FDA AI request that takes 45 days to respond to adds 45 days to the clearance timeline — plus the days FDA takes to review the response.

Missing the GPO contracting window. GPO contracts are negotiated on annual or biennial cycles. Hospital systems buy through GPO contracts, not off-contract. Missing the window means waiting another cycle.

A realistic, dependency-aware Gantt chart for medical device launch is the difference between a launch that hits its market window and one that misses it by a year.